net dbt
stori compel upgrad buy/top pick
upgrad buy commerci stabil po
upgrad buy neutral rais po
ebitda pf dmg sale commerci mix price appear
stabil bode well particularli given conserv initi guidanc
meanwhil view sale davita medic group dmg posit
use proce share repo debt repay invest also see upsid
epo save shift tax reform current trade
ebitda pf dmg sale attract price near histor average even though
tax reform boost cf see catalyst top hc facil pick
strong organ growth period moder volum
dialysi stabl recur busi good roi industri volum grow
see elsewher health care help compani leverag
fix cost off-set reimburs pressur ss volum growth view
sustain diabet obes hypertens main caus kidney failur
grow faster overal popul period moder volum broadli
dialysi stand well posit
commerci mix price stabil
reg charit premium assist creat overhang throughout
experienc commerci mix price pressur core dialysi
busi howev sever quarter stabl revenu per treatment posit
commentari payer contract give us confid head
dmg sale posit share repo nice accret
dmg perform disappoint sale allow focu
core kidney busi use half proce share repo paid
debt faster estim would add ep meanwhil
reinvest ancillari servic could also serv upsid
estim save gener epo come market could add ep
shift toward medicar advantag capit could creat lt tailwind
dialysi provid typic slightli profit patient vs lose money fee
servic medicar patient everi shift capit could add ep
final larg domest compani high tax rate would benefit tax
reform boost cf estim account tax reform share repo
debt repay epo save would trade pe vs current
commerci price stabil bear watch estim everi
hit commerci price would reduc oper incom oi addit
expect reg focu individu market employ group medigap
market outlin individu market exposur
dialysi oi could risk final dialysi staf rule consider
dva largest state ca could increas labor cost slow de novo growth state
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
health facil manag addit thought
dmg sale benefit vertic integr
davita inc dmg sale win/win
davita inc dmg acquir larg ipa network strateg
altern still play
davita inc show dmg still way go littl growth
dialysi final dialysi reg slightli wors
propos line model
health facil strong esco perform program
year implic
davita inc like continu worst case impact appear
davita inc commerci exposur lower expect
davita inc takeaway global hc confer london
continu debat next session
davita inc solid commerci commentari comfort
smaller impact
health facil delay fda approv epo
biosimilar still expect launch
health facil potenti approv epo biosimilar
could gener cost save
davita inc quarter line near term headwind persist
health facil clock strike midnight parti
rule damag alreadi done
health facil rule third parti premium support
delay posit dialysi provid
davita inc guidanc expect despit new
health dialysi primer unfilt look stabl
po base ebitda estim high end
stand-alon histor rang ebitda commerci outlook
stabil dmg sale allow focu core dialysi busi
upsid risk po commerci mix better expect
reimburs better expect make chang third
downsid risk po commerci price pressur could continu
potenti commerci mix pressur manag care vast major dialysi
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
